166 related articles for article (PubMed ID: 30442374)
21. [BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure].
Valle R; Aspromonte N; Carbonieri E; De Michele G; Di Tano G; Giovinazzo P; Cioè R; Di Giacomo T; Milani L; Noventa F; Chiatto M
Monaldi Arch Chest Dis; 2007 Sep; 68(3):154-64. PubMed ID: 18361212
[TBL] [Abstract][Full Text] [Related]
22. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
Zieliński T
Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
[No Abstract] [Full Text] [Related]
23. Tumour biomarkers in heart failure: is there a role for CA-125?
Yilmaz MB; Nikolaou M; Cohen Solal A
Eur J Heart Fail; 2011 Jun; 13(6):579-83. PubMed ID: 21525015
[TBL] [Abstract][Full Text] [Related]
24. Value of BNP and tumour marker CA125 in patients with heart failure.
Chen YX; Wang XQ; Fang CF; Wang JF; Tang LJ
Acta Cardiol; 2008 Aug; 63(4):501-6. PubMed ID: 18795589
[TBL] [Abstract][Full Text] [Related]
25. [Benefits of statin therapy based on plasma carbohydrate antigen 125 values following an admission for acute heart failure].
Núñez J; Sanchis J; Núñez E; Fonarow GC; Bodí V; Bertomeu-González V; Miñana G; Palau P; Fácila L; Chorro FJ; Bertomeu-Martínez V; Llàcer A
Rev Esp Cardiol; 2011 Dec; 64(12):1100-8. PubMed ID: 21958731
[TBL] [Abstract][Full Text] [Related]
26. Combining echo and natriuretic peptides to guide heart failure care in the outpatient setting: A position paper.
Dini FL; Carluccio E; Montecucco F; Rosa GM; Fontanive P
Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29044493
[TBL] [Abstract][Full Text] [Related]
27. Clinical findings, natriuretic peptides, and echocardiography: integrating tools to optimize heart failure management.
Beck-da-Silva L; Rohde LE; Goldraich L; Clausell N
Congest Heart Fail; 2007; 13(3):158-63. PubMed ID: 17541310
[TBL] [Abstract][Full Text] [Related]
28. Using Biomarkers to Guide Heart Failure Therapy.
Jaffe AS; Januzzi JL
Clin Chem; 2017 May; 63(5):954-957. PubMed ID: 28280051
[No Abstract] [Full Text] [Related]
29. Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction.
Falcão FJA; Oliveira FRA; Cantarelli F; Cantarelli R; Brito-Júnior P; Lemos H; Silva P; Camboim I; Freire MC; Carvalho O; Sobral-Filho DC
Braz J Med Biol Res; 2019; 52(12):e9124. PubMed ID: 31826182
[TBL] [Abstract][Full Text] [Related]
30. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.
Pacho C; Domingo M; Núñez R; Lupón J; Núñez J; Barallat J; Moliner P; de Antonio M; Santesmases J; Cediel G; Roura S; Pastor MC; Tor J; Bayes-Genis A
BMC Geriatr; 2018 May; 18(1):109. PubMed ID: 29743019
[TBL] [Abstract][Full Text] [Related]
31. Can Carbohydrate Antigen-125 Be a New Biomarker to Guide Heart Failure Treatment?: The CHANCE-HF Trial.
D'Aloia A; Vizzardi E; Metra M
JACC Heart Fail; 2016 Nov; 4(11):844-846. PubMed ID: 27810078
[No Abstract] [Full Text] [Related]
32. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report.
Faggiano P; D'Aloia A; Bignotti T; Dei Cas L
Ital Heart J; 2003 Jul; 4(7):497-9. PubMed ID: 14558304
[TBL] [Abstract][Full Text] [Related]
33. A mouse model of heart failure exhibiting pulmonary edema and pleural effusion: Useful for testing new drugs.
Ma X; Tannu S; Allocco J; Pan J; Dipiero J; Wong P
J Pharmacol Toxicol Methods; 2019; 96():78-86. PubMed ID: 30738210
[TBL] [Abstract][Full Text] [Related]
34. Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients.
Kaya H; Zorlu A; Yucel H; Tatlisu MA; Kivrak T; Coskun A; Yilmaz MB
Acta Cardiol; 2016 Feb; 71(1):61-6. PubMed ID: 26853255
[TBL] [Abstract][Full Text] [Related]
35. Copeptin in Heart Failure.
Balling L; Gustafsson F
Adv Clin Chem; 2016; 73():29-64. PubMed ID: 26975969
[TBL] [Abstract][Full Text] [Related]
36. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
Van Aelst LNL; Arrigo M; Placido R; Akiyama E; Girerd N; Zannad F; Manivet P; Rossignol P; Badoz M; Sadoune M; Launay JM; Gayat E; Lam CSP; Cohen-Solal A; Mebazaa A; Seronde MF
Eur J Heart Fail; 2018 Apr; 20(4):738-747. PubMed ID: 29251818
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
[TBL] [Abstract][Full Text] [Related]
38. Tumour markers in chronic heart failure. Review of the literature and clinical implications.
Faggiano P; D'Aloia A; Antonini-Canterin F; Vizzardi E; Nicolosi GL; Cas LD
J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):573-9. PubMed ID: 16858234
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
Masson S; Batkai S; Beermann J; Bär C; Pfanne A; Thum S; Magnoli M; Balconi G; Nicolosi GL; Tavazzi L; Latini R; Thum T
Eur J Heart Fail; 2018 Jan; 20(1):78-85. PubMed ID: 29027324
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week.
Aimo A; Januzzi JL; Bayes-Genis A; Vergaro G; Sciarrone P; Passino C; Emdin M
J Am Coll Cardiol; 2019 Oct; 74(17):2193-2203. PubMed ID: 31648713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
